Literature DB >> 28609635

SPX-101 Is a Promising and Novel Nebulized ENaC Inhibitor.

Alison Lennox1, Mike M Myerburg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28609635      PMCID： PMC5620681          DOI： 10.1164/rccm.201705-0928ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  16 in total

Review 1.  Mucus clearance as a primary innate defense mechanism for mammalian airways.

Authors:  Michael R Knowles; Richard C Boucher
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis.

Authors:  Mike M Myerburg; Michael B Butterworth; Erin E McKenna; Kathryn W Peters; Raymond A Frizzell; Thomas R Kleyman; Joseph M Pilewski
Journal:  J Biol Chem       Date:  2006-07-26       Impact factor: 5.157

3.  Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures.

Authors:  Carey A Hobbs; Maxime G Blanchard; Omar Alijevic; Chong Da Tan; Stephan Kellenberger; Sompop Bencharit; Rui Cao; Mehmet Kesimer; William G Walton; Ashley G Henderson; Matthew R Redinbo; M Jackson Stutts; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-11       Impact factor: 5.464

4.  SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.

Authors:  David W Scott; Matthew P Walker; Juliana Sesma; Bryant Wu; Timothy J Stuhlmiller; Juan R Sabater; William M Abraham; Timothy M Crowder; Dale J Christensen; Robert Tarran
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

5.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline.

Authors:  Scott H Donaldson; William D Bennett; Kirby L Zeman; Michael R Knowles; Robert Tarran; Richard C Boucher
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

6.  Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways.

Authors:  Alaina L Garland; William G Walton; Raymond D Coakley; Chong D Tan; Rodney C Gilmore; Carey A Hobbs; Ashutosh Tripathy; Lucy A Clunes; Sompop Bencharit; M Jackson Stutts; Laurie Betts; Matthew R Redinbo; Robert Tarran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

7.  Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.

Authors:  Marcus Mall; Barbara R Grubb; Jack R Harkema; Wanda K O'Neal; Richard C Boucher
Journal:  Nat Med       Date:  2004-04-11       Impact factor: 53.440

8.  Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.

Authors:  H Matsui; B R Grubb; R Tarran; S H Randell; J T Gatzy; C W Davis; R C Boucher
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

9.  SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage.

Authors:  Agustin Garcia-Caballero; Julia E Rasmussen; Erol Gaillard; Michael J Watson; John C Olsen; Scott H Donaldson; M Jackson Stutts; Robert Tarran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-18       Impact factor: 11.205

10.  Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia.

Authors:  Robert Tarran; Laura Trout; Scott H Donaldson; Richard C Boucher
Journal:  J Gen Physiol       Date:  2006-05       Impact factor: 4.086
View more
  2 in total

Review 1.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

2.  Novel therapeutic approaches for the management of cystic fibrosis.

Authors:  Ryan Jaques; Arslan Shakeel; Cameron Hoyle
Journal:  Multidiscip Respir Med       Date:  2020-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.